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Type 1 diabetes (T1D) results from a T-cell mediated destruction of pancreatic beta 
cells following the infiltration of leukocytes (including CD8+, CD4+ and CD20+ cells) 
into and around pancreatic islets (“insulitis”). Recently, we reported that two distinct 
patterns of insulitis occur in patients with recent-onset T1D from the UK and that these 
differ principally in the proportion of infiltrating CD20+ B-cells (designated “CD20Hi” 
and “CD20Lo” respectively). We have now extended this analysis to include patients 
from the nPOD (USA) and DiViD (Norway) cohorts and confirm that the two profiles of 
insulitis occur more widely. Moreover, we show that patients can be directly stratified 
according to their insulitic profile and that those receiving a diagnosis before the age of 
7 years always display the CD20Hi profile. By contrast, individuals diagnosed beyond 
the age of 13 years are uniformly defined as CD20Lo. This implies that the two forms of 
insulitis are differentially aggressive and that patients with a CD20Hi profile lose their 
beta cells at a more rapid rate. In support of this, we also find that the proportion of 
residual insulin-containing islets (ICIs) increases in parallel with age at onset of T1D. 
Importantly, those diagnosed in, or beyond, their teenage years retain ~40% ICIs at 
diagnosis, implying that a functional deficit rather than absolute beta cell loss may be 
causal for disease onset in these patients. We conclude that appropriate patient 
stratification will be critical for correct interpretation of the outcomes of intervention 
therapies targeted to islet-infiltrating immune cells in T1D.    
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Type 1 diabetes (T1D) is widely perceived as an autoimmune condition arising from the 
selective destruction of pancreatic β-cells by influent immune cells targeted to the islets of 
Langerhans (1-4). This concept has been examined extensively in animal models but many 
fewer studies have been undertaken in humans. Indeed, In’t Veld has noted that as few as 150 
T1D cases with insulitis have been scrutinized worldwide since the beginning of the last 
century (5; 6). This is unfortunate because the extent of insulitis observed in animal models is 
more fulminant than in most human patients, implying that additional studies are required to 
improve our understanding of the process in humans (5). Accordingly, we have exploited a 
large collection of autopsy pancreas samples recovered from patients who died soon after the 
diagnosis of T1D, to investigate the immune infiltrate in inflamed islets (2; 7; 8). This has 
revealed aspects of the temporal changes which accompany β-cell destruction and has shown 
that the principal cells involved in the destructive process are likely to be CD8+ cytotoxic T-
cells (2; 7; 8). However, the studies also yielded a more unexpected outcome in that they 
revealed a potential role for CD20+ B-cells in some patients based on the finding that these 
cells infiltrate islets in large numbers, in parallel with the influx of CD8+ T-cells (7).  
Building on this background, we have also highlighted an unexpected dichotomy in the 
composition of the immune cell infiltrates present in the inflamed islets of patients with 
recent-onset T1D (8). Thus, it was found that while significant numbers of CD20+ B-cells 
infiltrate the islets in many individuals; this is not universally true. Rather, other patients 
could be found in whose inflamed islets very few CD20+ cells were present. To denote this 
difference, the terms “CD20Hi” and “CD20Lo” were coined to differentiate the two profiles 
of insulitis and it was shown that each was present among a group of recent-onset patients 
diagnosed with T1D before the age of 20 years (8). Importantly, it was also noted that the 
variation in B-cell numbers occurs independently of the presence of CD8+ T-cells. Despite 
this, it was also clear that the total population of infiltrating immune cells is least abundant in 
cases where CD20+ cell numbers are depleted. Accordingly, the two states might also be 
considered as relatively “hyper-immune” (CD20Hi) or “pauci-immune” (CD20Lo), 
respectively. 
In order to develop a greater understanding of the functional significance of these two 
insulitic profiles in human T1D, we now report a more complete characterization of the 
phenomenon in three different pancreas collections: those harvested at post-mortem (UK) (9), 
biopsies from living donors (DiViD; Norway (10)) and samples from organ donors (nPOD; 
USA (11; 12)). The studies confirm the existence of two distinct profiles of insulitis and 
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imply that these patterns exert a profound influence on the rate of disease progression and the 
extent of β-cell destruction in humans. As such, these new results suggest very strongly that 
correct patient stratification will be essential when testing the efficacy of targeted 
immunotherapeutic agents in human populations, and imply that caution should be exercised 
when interpreting the outcomes of earlier trials where this was not achieved.  
 
Experimental 
Pancreas samples 
Insulitis was examined in 21 human pancreas sections recovered at the time of post-mortem 
from patients among a UK cohort of patients with T1D who had died within 3 months of 
diagnosis (7; 9). These comprised 14 female and 7 males with ages ranging from 1–19 years 
(mean 10.1 ± 1.3y). For studies of the extent of residual insulin positivity, sections from all 
151 patients within this collection were evaluated, irrespective of disease duration or the 
presence of insulitis (63 males; 88 females). 
In addition, insulitis was also studied in pancreas sections recovered by laparoscopic minimal 
tail resection from 6 living adult donors who had participated in the DiViD study (10), as 
well as in 2 organ donors with recent-onset T1D from the nPOD cohort (Table S1). 
Participants in the DiViD study were aged between 25-35 years and their biopsies were taken 
between 3-9 weeks after initial diagnosis. The 2 nPOD donors were 4.75y and 11y old at time 
of death and their disease duration was 120 days and 0 days respectively. Collection of 
pancreatic tissue in the DiViD study was approved by The Norwegian Governments Regional 
Ethics Committee and all samples were studied with ethical approval. 
Immunohistochemistry  
Serial sections (4 µm) were cut from each pancreas and mounted on glass slides. Samples 
from the UK cohort were processed and labelled using a standard immunoperoxidase 
technique for paraffin sections as described previously (7; 8).  All antigens, except insulin 
and glucagon, were unmasked by heat-induced epitope retrieval. In brief, sections to be 
labelled with anti-CD20+ anti-serum (M0755; Dako) were heated in 10mM citrate buffer, pH 
6 for 20 min in a microwave oven at full power (800W). Those to be labelled with anti-CD4
+
 
(ab846; Abcam) or anti-CD8+ (ab4055; Abcam) were heated in 10mM Tris, 1mM 
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ethylenediamine-tetraacetic acid, pH 9. Primary antibodies were applied for 1h at room 
temperature, with the exception of anti-CD4, which was incubated at 4°C overnight (Table 
S2). Antigen visualization was achieved via the Dako REAL™ Envision™ Detection 
System. Some slides were processed in the absence of primary antibody or with isotype 
control antisera to confirm the specificity of labelling. 
Pancreas sections from the DiViD and nPOD collections were examined by a combination of 
immunofluorescence and immunohistochemistry using horseradish peroxidase and alkaline 
phosphatase staining, as appropriate.  Where possible, and to minimize sample usage, at least 
two antigens per section were examined in parallel. Antigens were unmasked by heat-induced 
epitope retrieval (20 min at full power in a microwave oven; 800W) in 10 mmol/L citrate 
buffer (pH 6). Combined staining was achieved by using guinea pig anti-insulin (A0564; 
Dako) in combination with mouse anti-glucagon (ab10988; Abcam) and visualized using a 
Vector Red Substrate kit for detection of alkaline phosphatase activity (AK-5100 and SK- 
5100; Vector Laboratories, U.K.).  Binding of rabbit anti-CD8 and mouse anti-CD20 sera 
was visualized using secondary antibodies tagged with appropriate fluorescent probes 
(Alexafluor anti-mouse 488 (A11029; Invitrogen, Paisley, U.K.) or anti-rabbit 568 (A1136; 
Invitrogen)). Cell nuclei were stained with DAPI. 
Image acquisition and analysis 
Brightfield image acquisition and analysis were performed on a Nikon 50i Microscope fitted 
with a DS-Fi camera and DSL2 camera control unit. Images were captured and analyzed 
using the ImageJ platform. Immunofluorescence image collection and processing was 
achieved using a Leica DM4000 B LED upright fluorescence microscope and Leica Image 
analysis software (LAS AF). 
 
Statistical analysis 
10 islets were selected randomly from within each stained section among the UK cohort and 
the number of CD8+, CD4+ and CD20+ cells within the islet area and in the endocrine-
exocrine interface in close contact with the islet boundary were recorded. The mean number 
± SEM of each immune cell subtype was calculated for each patient as an average of the 10 
individual values from each islet. The insulin positive area of each islet was assessed and 
expressed as percentage of the total area as described previously and scored as (+++), (++) or 
(+) respectively.  In the DiViD and nPOD cohorts, immune cells were counted from ~30 
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islets per patient section and expressed as above. Statistical significance was calculated using 
Kruskal-Wallis with Dunn’s multiple comparison test, Student’s t-test or by Chi-squared 
analysis, as appropriate.  
 
Results 
Profiles of insulitis in patients with type 1 diabetes 
Detailed analysis was undertaken of the numbers of CD8+, CD4+ and CD20+ cells within, or 
in close proximity to, 10 randomly selected inflamed islets across multiple cases from among 
the UK collection of recent-onset T1D patients. This confirmed the existence of the two 
independent profiles (“CD20Hi” and “CD20Lo”; Fig.1A & B). The results also revealed that 
these profiles are patient-specific in that all inflamed islets within any given individual 
display the same phenotype.  
A more dynamic evaluation of the profile of immune cell infiltration in relation to β-cell loss 
was also undertaken in patients from each group (Fig.1 C-F). This analysis confirmed that 
CD8+ T-cells always comprise the majority population within inflamed islets, irrespective of 
the number of CD20+ cells present. This was evident both when the absolute number of each 
cell type was examined (Fig.1C & D) and when the relative proportions of each were 
calculated (Fig.1E & F).  It was also clear that the number of CD8+ T-cells varied according 
to the progression of beta-cell loss (Fig.1C & D). CD4+ T-cell numbers also tended to rise as 
the extent of β-cell loss neared totality but their absolute number (and relative proportion) 
was always much lower than the number (or proportion) of CD8+ cells. Importantly, the most 
marked difference between the two phenotypes was in the proportion of CD20+ B-cells 
found within, or near to, inflamed islets. Among one group (CD20Hi) these were abundant 
and they increased in parallel with the CD8+ cells as β-cell death progressed (Fig.1C, E). By 
contrast, in the second group (CD20Lo individuals) they were the least abundant cell type at 
all stages of the disease process (Fig.1D, F).  
In addition to the variation in the absolute number of CD20+ cells, the ratio of CD20+ to 
CD4+ cells also varied consistently between the two phenotypes (Fig.1). Thus, in CD20Hi 
cases the ratio of CD20+:CD4+ cells in inflamed islets was greater than 1.0 at all stages of β-
cell loss, whereas this ratio was consistently less than 1.0 in CD20Lo patients. On this basis, 
it seemed that estimation of the CD20+:CD4+ cell ratio might offer greater utility as a means 
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to sub-classify patients. Accordingly, we focused on this ratio to define the CD20Hi 
(CD20+:CD4+ >1.0) and CD20Lo (CD20+:CD4+ <1.0) sub-groups in subsequent studies.  
Since the two profiles of insulitis may represent differentially aggressive phenotypes with 
variable rates of disease progression (8), the ratio of CD20+:CD4+ cells was examined in 
patients from the UK at increasing age at diagnosis. This revealed a striking relationship 
despite the limitation that all patients studied had been diagnosed below the age of 20 years 
(Fig.2). Notably, it was clear that CD20Hi patients tended to be diagnosed at younger ages 
than those defined as CD20Lo. Indeed, when patients within the UK cohort were stratified 
into those diagnosed with T1D at between 1 and 6 years of age vs those diagnosed at 13 years 
or beyond, the separation between the two phenotypes was absolute (Fig.2). All individuals 
within the younger group were classified as CD20Hi while those diagnosed at the older age 
were CD20Lo. Patients who developed T1D between the ages of 7 and 13 years fell into 
either group.  
To verify these conclusions, we next examined the profile of insulitis in pancreas samples 
from among the nPOD collection and from the DiViD cohort of living organ donors. In 
practice, only two patients who met our criteria for recent-onset T1D (within 120 days of 
diagnosis) were available from nPOD (6209 and 6228) while all six of the DiViD patients 
conformed to this criterion. Strikingly, the insulitic profile in each of the inflamed islets of 
the six DiViD patients (all of whom were diagnosed beyond the age of 20 years) was 
CD20Lo (Fig.3). A similar profile was found in one of the two nPOD patients (6228; 
diagnosed originally at 13 years of age). By contrast, the second nPOD case (6209) was 
diagnosed much earlier in life (<5 years) and was defined as CD20Hi. 
The influence of age at diagnosis on the proportion of residual insulin-containing islets in the 
pancreases of patients with type 1 diabetes 
In view of the finding that age at diagnosis is predictive of the profile of insulitis in patients 
with recent-onset T1D, and that individuals diagnosed at younger ages appear to display a 
more aggressive phenotype, we considered the possibility that the proportion of residual 
insulin-containing islets (ICIs) might also differ between these groups. Accordingly, we 
calculated the proportion of such islets in sections of pancreas from each patient. This was 
achieved by using glucagon immunoreactivity to define the total islet number, with 
simultaneous co-staining for insulin to monitor the proportion of residual ICIs. Initially, this 
analysis was performed for the patients within the UK cohort and these were stratified 
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according to age: group 1) from 1-6 years at diagnosis; group 2) 7-12 years; group 3) 13 
years or greater. The results revealed a strongly positive relationship in which individuals 
who had been diagnosed at the youngest ages retained a much lower proportion of ICIs than 
those diagnosed in the older age group (p<0.001; Fig.4).  
Extending this analysis to include pancreas samples from the two additional nPOD cases as 
well as those from the six DiViD patients, reinforced these conclusions. Thus, the DiViD 
patients retained a mean of 25% ICIs in the pancreas sections studied, at diagnosis (Fig.4) 
and this was also the situation in nPOD 6228 (CD20Lo; Fig.4). By contrast, nPOD case 6209, 
whose insulitic profile was consistent with a more aggressive inflammatory infiltrate, 
retained only 10% ICIs at diagnosis.  
Having examined patients soon after diagnosis, the analysis was extended to include UK 
cases having a disease duration of between 1-10 years (Supplementary Fig. 1). Consistent 
with the data from recent–onset patients, individuals diagnosed at the younger ages retained 
fewest ICIs. 
In view of this striking outcome, we extended the dataset further to examine the entire 
collection of T1D pancreas samples available within the UK cohort (a total of 151 patients) 
irrespective of their disease duration or the presence of insulitis (Fig. 5). The proportion of 
residual ICIs present in at least one pancreatic section (selected randomly from those 
available for study) from each block was calculated. When stratified into three groups 
according to the original age at diagnosis (1-6 years; 7-12 years; >13 years) the proportion of 
residual ICIs increased from a mean of 14±3% in those diagnosed early in life, to 39±4% in 
those diagnosed from their teens or beyond (p<0.001). Indeed, among the latter group, 56 of 
69 patients still retained residual ICIs in the pancreas section studied. This was significantly 
more than the equivalent proportion among those in the youngest age group (19 of 43; 
p<0.004 by Chi squared analysis). Similar findings were made in the nPOD cohort when the 
proportion of cases with residual ICIs was examined (Supplementary Fig. 2 & Supplementary 
Table 2).   
 
Discussion 
It is often assumed that insulitis and β-cell loss proceed in a broadly consistent manner in the 
majority of patients developing T1D and that the final descent into clinical disease occurs 
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when a defined proportion of the initial β-cell mass has been lost.  Estimates vary as to the 
precise extent but it is frequently argued that >80% loss may be required to precipitate the 
disease (13-16). However, in accord with Klinke (17), we find that this may be an over-
simplification. Importantly, we note that β-cell numbers do not necessarily dwindle to very 
low levels before diabetes is manifest but that many patients become diabetic while still 
retaining significant numbers of these cells. We also find that the process and extent of β-cell 
loss varies with age such that individuals who develop T1D early in life (before the age of 7 
years) lose β-cells to a much greater extent than those who are diagnosed with the illness in 
their teenage years or beyond. Similar conclusions that patients with an early disease onset 
may have a more fulminant form of the illness have also been reached previously (18; 19) 
and we now attribute this variation to the existence of two distinct profiles of insulitis which 
yield very different rates of β-cell loss (8).  
Careful examination of multiple islets across a range of patients reveals that all of the 
inflamed islets within a given patient display the same insulitic profile but that this profile 
differs significantly between individuals. Importantly, this variation does not occur in a 
purely stochastic manner but, rather, two identifiable forms of insulitis can be differentiated. 
Both are characterized by a preponderance of CD8+ T-cells suggesting that these are likely to 
be the key cytotoxic mediators in each subtype of the disease. By contrast, there is much 
greater variation in the proportion of CD20+ B-cells; these are abundant in the inflamed islets 
of some individuals but are almost absent from the islets of others. As a result, the terms 
"CD20Hi" or "CD20Lo" were coined to denote these two profiles (8). This designation is not 
intended to imply that CD20+ cells are necessarily (or selectively) cytotoxic in one form of 
the disease but, rather, to emphasize that these cells may play an important accessory role in 
the destructive process, and that this is exerted more effectively in one form than in the other. 
Comparison of the number (or proportion) of CD4+ cells within inflamed islets revealed no 
significant differences among this cell population but suggested that they could provide a 
useful means to distinguish the two profiles, based on measurement of the ratio of CD20:CD4 
cells. Thus, among CD20Hi patients this ratio was greater than 1.0 while it was below 1.0 in 
those defined as CD20Lo. Accordingly, we propose that monitoring of the ratio of 
CD20:CD4 cells may provide a useful and robust means to distinguish the two subtypes of 
insulitis. 
The justification for our conclusion that the two profiles of insulitis are functionally different 
lies in the striking finding that children who develop diabetes below the age of 7 years 
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uniformly display a CD20Hi profile, while the islets of those patients diagnosed in or beyond 
their teenage years are always CD20Lo. This extraordinary level of differentiation was 
unexpected and it was important to establish that it did not reflect a hidden variable arising 
from the study of a individuals whose pancreas was harvested in a particular way or from one 
specific geographical region (the majority of our observations having been made using 
samples collected at autopsy in the UK from individuals who had died in ketoacidosis (9)). In 
noting this, it must also be emphasized that extending the analysis is not a trivial task because 
the number of recent onset T1D cases available for study worldwide is very small. 
Nevertheless, we were able to confirm the findings by analysis of two organ donors with 
recent onset T1D from the nPOD collection (6209 and 6228 (11; 12)) and six newly 
diagnosed adults who had consented to pancreatic biopsy in the Norwegian DiViD study 
(10). These followed identical patterns to those seen in the larger group from the UK and 
allowed the compilation of a more extensive dataset to verify the conclusions. This revealed 
statistically significant differences in several parameters assessed at the islet level between 
those diagnosed at younger ages (under 7 years) and those who were older at disease onset 
(13 years or over). Most notably, all patients diagnosed at >13 years displayed a CD20Lo 
islet profile while young children had a CD20Hi profile. Not surprisingly, individuals who 
were diagnosed with T1D between 7-12 years of age could fall into either category, as might 
be expected if two overlapping distribution profiles exist.  
Analysis of the age-related variation in disease pathology revealed a second important 
feature; namely that the proportion of ICIs remaining at diagnosis of T1D varies significantly 
between groups. Consistent with the results of a previous meta-analysis (17), we found that 
those diagnosed in their early years had a much lower proportion of ICIs than patients with 
an older age at onset. This difference was so pronounced that age at diagnosis could be used 
as a strong surrogate to predict the proportion of ICIs present at diagnosis and the profile of 
insulitis that would be found (whether CD20Hi or CD20Lo). Moreover, when this analysis 
was extended to include all 151 samples from within the UK cohort and 116 from nPOD 
(irrespective of disease duration) stratified according to age at diagnosis, these relationships 
still held. Younger patients (aged under 7 years) had a significantly lower proportion of 
residual ICIs than those who presented with T1D in their teenage years or beyond (even when 
many years had passed between the initial diagnosis and the availability of the pancreas for 
analysis). 
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In drawing this conclusion it is important to recognize that the present analysis was 
undertaken on only a small number of sections from any given pancreas. Indeed, in many 
cases the proportion of ICIs was estimated on a single section. This then raises an important 
question about the extent to which an individual set of data derived from one section can be 
considered representative of the entire pancreas. This is especially true given that the 
processes of insulitis and β-cell loss occur in a lobular manner across the gland (20-23). Such 
considerations inevitably mean that it would be dangerous to draw firm conclusions from a 
single pancreatic section taken from one individual patient studied in isolation. However, a 
key strength of the present study is that we were able to examine sections selected at random 
from multiple patients and thereby to counter the likelihood of systematic bias. On this basis, 
we consider that the cumulative results provide a representative view of the pathological 
mechanisms causing T1D and that wider generalization of the conclusions is valid. If this 
were not the case, then factors such as the proportion of ICIs would be expected to distribute 
more randomly in the analysis rather than segregating in parallel with age at disease onset, as 
we find. 
The discovery that many patients develop T1D at a time when their β-cell mass remains 
relatively high suggests that, in these individuals, β-cell dysfunction rather than cell death 
may be a significant contributory factor leading to glucose intolerance. Indeed, this is 
supported directly by study of the insulin secretory capacity of the islets isolated from 
pancreas biopsies recovered from the DiViD cohort (24). These patients all displayed a 
CD20Lo profile of insulitis and, in accord with this, they were diagnosed beyond their 
teenage years and they retained a large proportion of ICIs at disease onset. Importantly, their 
islets were largely unresponsive to a glucose stimulus upon isolation but gradually regained 
responsiveness during tissue culture under ex vivo conditions (24). This implies that the ICIs 
had become dysfunctional in vivo rather than experiencing an irreversible decline arising 
from complete β-cell demise. These results therefore offer the prospect that, by appropriate 
therapeutic intervention, the residual β-cells of patients with a CD20Lo insulitic profile might 
also be reactivated in vivo and that, in combination with an appropriate immunotherapeutic 
regime, this could lead to a reduced requirement for exogenous insulin.  
One important conclusion arising from the present data is that due care should be exercised 
when designing immunotherapeutic interventions in patients with T1D. In particular, it will 
be important to ensure that patients are stratified according to their insulitic profile (for which 
age at onset appears a strong surrogate) and that the regimen is tailored appropriately. One 
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obvious example to illustrate this principle arises from the outcome of trials with the anti-
CD20 monoclonal antibody, rituximab (25; 26). Since we find that infiltrating CD20+ cells 
are present preferentially in the islets of patients diagnosed below the age of 7 years it is, 
perhaps, likely that such individuals may be most sensitive to the therapy whereas older 
patients will be more refractory.  
In conclusion, we confirm that insulitis occurs in two distinct profiles in patients with T1D. 
These differ principally in the proportion of CD20+ B-cells (expressed relative to CD4+ 
cells) present within the infiltrate and this appears to lead to a more or less aggressive 
phenotype respectively. Not only do these phenotypes lead to differential rates of β-cells loss 
(as judged by marked differences in the age at onset between the groups) but they also 
culminate in loss of glucose tolerance when dramatically different numbers of β-cells remain 
in the pancreas. In the youngest patients, β-cell loss is rapid and extensive. By contrast, those 
diagnosed in their teenage years or beyond, have a less aggressive disease and they 
experience clinical onset when a significant β-cell reserve is still measurable. These results 
emphasize that, in the future, it will be critical to stratify patients appropriately according to 
their insulitic profile and age at onset of disease in order to design and trial effective therapies 
for T1D. 
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Figure 1. Complement of immune cells in inflamed islets of patients with type 1 
diabetes.  The numbers of CD8+ (circles), CD4+ (squares) and CD20+ (triangles) cells were 
quantified in at least 10 inflamed islets in each of 20 pancreases available within the UK 
cohort of recent-onset T1D patients. These are displayed as the cumulative mean values per 
islet (±SEM) of each cell type, stratified according to the average number of CD20+ cells 
present. Left hand panels (A,C,E) are from patients with a mean of >3 CD20+ cells per 
inflamed islet (10 cases); right hand panels (B,D,F) are from those with <3 CD20+ cells per 
inflamed islet (10 cases). Panels A & B show the average number of immune cells per islet 
independent of islet insulin content. Panels C-F show the data analyzed in relation to the 
insulin content of each islet; displayed either as the absolute mean number of immune cells 
(C & D) or as the relative proportion of each immune cell subtype (E & F). Islet insulin 
content was calculated relative to total islet area and is expressed as (+++) (++) (+) and (-) to 
denote decreasing insulin immunopositivity (>65%; 33-64%; <33% and zero, respectively). 
 
Figure 2. Ratio of CD20+:CD4+ cells in the inflamed islets of patients with type 1 
diabetes from the UK cohort. Patients with recent-onset T1D from within the UK cohort 
were stratified according to their age at diagnosis of diabetes and the ratio of CD20+:CD4+ 
cells calculated in 10 inflamed islets from each patient. Each point represents the mean ratio 
in an individual patient and the differentially hatched panels define the increasing age ranges 
at diagnosis (1-6 years (left; stippled pattern) 7-13 years (centre; diagonal hatches) and 14-20 
years (right; horizontal hatches)). 
 
Figure 3. Ratio of CD20+:CD4+ cells in the inflamed islets of patients with type 1 
diabetes from multiple cohorts. Islets were examined in pancreas samples from patients 
with recent-onset T1D among the UK cohort (circles) the nPOD collection (squares) and the 
DiViD cohort (triangles) and stratified according to their age at diagnosis of diabetes. The 
ratio of CD20+:CD4+ cells was calculated in up to 30 inflamed islets from each patient. Each 
point represents the mean ratio in an individual patient displayed in relation to their age at 
diagnosis. 
*p<0.001 relative to those diagnosed at 1-6 years. 
 
Page 14 of 26Diabetes
  
Figure 4. Proportion of residual insulin-containing islets found in pancreas sections 
from patients with recent-onset type 1 diabetes. The proportion of insulin-containing islets 
(expressed as %) in pancreatic sections from patients with recent-onset T1D among the UK 
cohort was determined and displayed in relation to the age at diagnosis. Arrows indicate the 
equivalent values in the 6 patients from the DiViD cohort (all of whom were diagnosed 
beyond the age of 20 years) and the 2 nPOD cases (6228; diagnosed at 13y; 6209 diagnosed 
at <5y).  
*P<0.001 relative to those diagnosed at 1-6 years. 
 
Figure 5. Proportion of residual insulin-containing islets found in pancreas sections 
from 151 patients with type 1 diabetes among the UK cohort, irrespective of disease 
duration. The proportion of residual insulin-containing islets was calculated (%) in at least 
one pancreatic section from all 151 patients with type 1 diabetes among the UK cohort. These 
were then stratified into 3 groups according to their age at initial diagnosis of T1D. 
*p<0.001 relative to those aged 1-6 years. 
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Supplementary table 1. Characteristics  of the patients studied from among the nPOD and DiViD 
cohorts.  
 
 
Patient No 
Age at 
diagnosis 
Gender 
Duration 
(weeks) 
DiViD 1 25 F 4 
DiViD 2 24 M 3 
DiViD 3 34 F 9 
DiViD 4 31 M 5 
DiViD 5 24 F 5 
DiViD 6 35 M 5 
nPOD 6209-01PB 4.75 F <13 
nPOD 6228-04PB 13 M 0 
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Supplementary Table 2: Retention of insulin-containing islets in nPOD cases stratified according to 
age at onset and duration of disease (1-10y and 11-25y).  
The proportion of cases with residual ICIs declines with disease duration but this effect is least 
marked in those diagnosed in their teenage years and beyond (when almost 40% of patients still 
retain ICIs at up to 25 years of disease duration). 
 
 All cases regardless of 
duration 
Duration 1-10y Duration 11-25y 
Age at 
diagnosis 
(years) 
Total No. 
cases (N) 
Cases  with 
residual 
ICIs/ N 
(%) 
Total No. 
cases (N) 
Cases  with 
residual 
ICIs/ N 
(%) 
Total No. 
cases (N) 
Cases  with 
residual 
ICIs/ N 
(%) 
1-6y 33 6/33 (18.2) 8 3/8 (37.5) 8 0/8   (0.0) 
7-12y 32 9/32 (25.0) 9 6/9 (66.7) 13 2/13 (15.4) 
>13y 51 25/51 (49.0) 22 14/22 (63.6) 22 8/22 (36.4) 
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Supplementary Figure 1:  
(A) Proportion of residual insulin-containing islets found in pancreas sections from  44 patients with 
type 1 diabetes among the UK cohort  (disease duration of 1-10 years). These were stratified into 3 
groups according to their age at initial diagnosis of T1D; 1-6y (n=16; red circles), 7-12y (n=14; blue 
triangles) and >13y (n=14; green squares). The data show that individuals diagnosed at younger ages 
have fewest residual ICIs. This difference is statistically significant between the 1-6y vs >13y age 
groups (p<0.006). 
 
(B) Proportion of residual ICIs in patients who died 1-10y post-diagnosis of T1D stratified according 
to age at onset of disease. The residual ICIs (mean ± SEM %) differed significantly at increasing ages 
at onset; ** p<0.01; * p<0.05.  
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Supplementary Figure 2: Proportion of cases with residual insulin-containing islets found in pancreas 
sections with type 1 diabetes among the nPOD cohort. Data were extracted from the histopathology 
reports available at: https://npoddatashare.coh.org/labkey/login/home/login.view.  
Among 116 patients studied, a total of 40 had residual insulin-containing islets at the time of death. 
When cases were stratified based on the age at diagnosis, it was revealed that more of those 
diagnosed at >13 years retained ICIs than diagnosed earlier irrespective of duration of disease  (Chi 
squared; P=0.0067).  
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